Survival in patients with newly diagnosed conventional glioblastoma: A modified prognostic score based on a single-institution series

Tumori

Volumn 98, Issue 6, 2012, Pages 756-761

  Bertolini, Federica ^a   Zunarelli, Elena ^a   Baraldi, Caterina ^a   Valentini, Antonella ^b   Cinzia Del, Giovane ^a   Depenni, Roberta ^a   Falasca, Angelo ^b   Giacobazzi, Patrizia ^a   Malagoli, Marcella ^b   Meletti, Stefano ^b   Fontana, Annalisa ^a   Conte, Pier Franco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

Author keywords

Clinical variables; Glioblastoma; MGMT; Molecular variables; Prognostic score

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; ECOG PERFORMANCE STATUS; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE GENE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROMOTER REGION; RECURSIVE PARTITIONING ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TUMOR BIOPSY;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84873684496     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800613     Document Type: Article

References (19)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114: 97-109, 2007.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987-996, 2005.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10: 459-466, 2009.
4. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 85: 704-710, 1993.
5. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol, 24: 2563-2569, 2006.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352: 997-1003, 2005.
7. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol, 26: 4189-4199, 2008.
8. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol, 9: 29-38, 2008.
9. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ: A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin fixed paraffin-embedded tissue. Lab Invest, 87: 392-397, 2007.
10. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ Jr: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys, 40: 51-55, 1998.
11. Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P: Phase III two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or ≤20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys, 48: 1351-1358, 2000.
12. Fisher B, Won M, Macdonald D, Johnson DW, Roa W: Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys, 53: 980-986, 2002.
13. Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, Curran W: Phase II Radiation Therapy Oncology Group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 51: 113-119, 2001.
14. Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, Shenouda G, Souhami L: The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys, 58: 247-252, 2004.
15. Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol, 6: 227-235, 2004.
16. Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B: Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol, 18: 1254-1259, 2000.
17. Miralbell R, Mornex F, Greiner R, Bolla M, Storme G, Hulshof M, Bernier J, Denekamp J, Rojas AM, Pierart M, van Glabbeke M, Mirimanoff RO: Accelerated radiotherapy, carbogen and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol, 17: 3143-3149, 1999.
18. Sarkaria JH, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Levin AB, Alexander E 3rd, Friedman WA, Kinsella TJ: Radiosurgery in the initial management of malignant gliomas: Survival comparison with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys, 32: 931-941, 1995.
19. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360: 765-773, 2009.